玮俊生物科技(00660)发盈警 预期年度净亏损同比扩大至5700万至6200万港元

智通财经
16 Dec 2024

智通财经APP讯,玮俊生物科技(00660)发布公告,集团预期截至2024年6月30日止年度(本年度)将取得综合净亏损介乎5700万港元至6200万港元,而截至2023年6月30日止年度净亏损约1000万港元。

公告称,预期公司综合净亏损增加主要是由于(其中包括)毛利减少约1620万港元及物业、厂房及设备减值亏损约5180万港元。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10